Reactivation of Latent Tuberculosis Following COVID-19 and Epstein-Barr Virus Coinfection: A Case Report.

Iryna Halabitska, Pavlo Petakh, Valentyn Oksenych, Oleksandr Kamyshnyi

Abstract readCase Reports

In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Molecular signaling in coinfection: howFrontiers in immunology · 2026
Review
Secondary infections following tuberculosis: epidemiology, pathogenesis and clinical implications.Breathe (Sheffield, England) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Iryna HalabitskaDepartment of Therapy and Family Medicine, I. Horbachevsky Ternopil National Medical University, Voli Square, 1, 46001 Ternopil, Ukraine.ORCID 0000-0002-9028-7230

Pavlo PetakhDepartment of Biochemistry and Pharmacology, Uzhhorod National University, 88000 Uzhhorod, Ukraine.ORCID 0000-0002-0860-4445

Valentyn OksenychBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.ORCID 0000-0002-5088-3791

Oleksandr KamyshnyiDepartment of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0003-3141-4436

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CoinfectionCOVID-19Epstein-Barr Virus InfectionsLatent TuberculosisAntitubercular AgentsFemaleHerpesvirus 4, HumanHumansSARS-CoV-2Virus ActivationYoung AdultAntitubercular AgentsCOVID-19Epstein–Barr viruslymphadenopathylymphopeniaMycobacterium tuberculosisscrofuloderma

Identifiers

PMID40430808

DOI10.3390/pathogens14050488

PMCPMC12114845

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.